PrecisionLife is at the forefront of transforming the future of precision medicine by uncovering the deepest insights into disease biology.  

Through its advanced combinatorial analytics platform, PrecisionLife can decipher the biological mechanisms driving diseases within patient subgroups at an unprecedented level of detail, setting a new standard in the field. 

This profound understanding powers PrecisionLife’s Innovation Engine, which drives patient-focused drug discovery and the development of personalised therapies for chronic diseases such as dementia, diabetes, cardiovascular, and autoimmune disorders. By precisely stratifying patient populations, the company uncovers novel drug targets, repositions existing drugs, and identifies biomarkers to ensure that the most effective treatments are tailored to each individual patient. 

To date, the business has analysed 45 complex chronic diseases, identified over 250 precision repositioning opportunities to enhance existing drugs and discovered over 300 novel drug targets (a specific molecule in the body, often a protein, that a drug interacts with to produce a therapeutic effect - a crucial step in new drug development). 

PrecisionLife is leading the charge into a new era of precision medicine, where complex chronic diseases are no longer addressed with a one-size-fits-all approach. Instead, the company enables more accurate diagnoses, better disease prediction, and highly effective, individualised treatments.

For more information visit www.precisionlife.com